Clinical trial · Interventional
Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk
Evaluating Changes in Cardiac Function During Stress Echocardiography for the Identification of Chemotherapy Induced Cardiotoxicity in Cancer Patients at Risk of Developing Heart Failure
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial evaluates changes in cardiac (heart) function during stress echocardiography to screen for chemically induced cardiotoxicity in cancer patients at a high risk for developing heart failure. Some chemotherapeutic agents to treat certain types of cancers can induce cardiac dysfunction and heart failure. Currently there is no validated means of predicting which patients will go on to develop cardiac toxicity and heart failure following treatment with chemotherapeutic agents. Stress echocardiography is a test that uses ultrasound imaging to show how well the heart muscle is working to pump blood to the body during low intensity exercise. Stress echocardiography prior to and during cancer treatment may help doctors find cancer therapeutic related cardiac dysfunction sooner when it may be easier to treat.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematopoietic and Lymphoid System Neoplasm | Hematopoietic and Lymphatic System Neoplasm | ALIAS | 0.90 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Echocardiography | Procedure | — | UNRESOLVED |
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
| Stress Echocardiography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group I (resting and/or stress echocardiography)
- description
- Patients choose to undergo either a resting echocardiography performed before and after delivery of a cancer therapeutic agent and months 3, 6, 9 and 12 or up to 5 low intensity stress echocardiography over 25 minutes performed depending on where they are at in the course of their cancer therapy and/or cardiac rehabilitation program at baseline and/or months 3, 6, 9 and 12 after starting cancer therapy.
- interventionNames
- Procedure: Echocardiography
- Other: Electronic Health Record Review
- Other: Questionnaire Administration
- Procedure: Stress Echocardiography
- type
- ACTIVE_COMPARATOR
- label
- Group II (stress echocardiography)
- description
- Participants undergo low intensity stress echocardiography over 25 minutes at baseline and may undergo a second one at least 24 hours later.
- interventionNames
- Procedure: Stress Echocardiography
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Current or previous diagnosis of solid organ cancers (breast, non-small cell lung, rectal, renal, hepatic cancer, metastatic melanoma, sarcoma) or hematological disease (lymphoma, leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance \[MGUS\]) * Age \>= 18 years at study enrollment * Plan to receive, or history of having received, chemotherapy (anthracycline, alkylating agent \[cyclophosphamide, ifosfamide\], and/or antimicrotubule agent \[docetaxel, paclitaxel\]) with or without specific targeted therapies; * Anti-HER2 targeted therapies (trastuzumab, pertuzumab) * Vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, vandetanib) * Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) * Plan to undergo conditioning chemotherapy for bone marrow transplantation (autologous/allogeneic) Exclusion Criteria: * Coronary artery disease * Significant (more than mild) valvular heart disease * Pre-existing heart failure * Pre-existing cardiomyopathy * Musculoskeletal or neurologic abnormality prohibiting low intensity exercise on a stationary bicycle * Severe pulmonary disease limiting ability to perform low intensity exercise on a stationary bicycle
References
Publications (0)
Data not yet available